Neonc Technologies, Inc.

NTHI · Nasdaq · United States

Share price · NTHI

$4.16-1.37 (-24.77%) 3M

close as of 2026-11-18 · 24h delayed · vol 280K (1.6x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when NTHI's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 10 Nov 2026+16.8%
  2. 8 Sep 2026-19.1%
  3. 19 Aug 2026-16.3%
  4. 14 Aug 2026+31.5%
  5. 12 Aug 2026-20.5%
  6. 11 Aug 2026+24.3%
  7. 14 Jul 2026-14.8%
  8. 16 Jun 2026+14.9%
  9. 8 May 2026-16.0%
  10. 7 May 2026+22.2%

Share of unusual movement by asset

For each asset, the share of NTHI's own-move activity since 27 Mar 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
NEO100
events and moves
115%
NEO212
events and moves
113%
Other company news (earnings, financing, releases naming no asset)—29%
Sessions with no dated event—63%

Assets

(2 total)
2Total Assets
0Approved
0Phase 3 / Filed
2Phase 1–2 / Early
3Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Phase 1/2
DNA (guanine N7 position)Small molecule
Non-Small Cell Lung CancerBrain Cancer
Malignant Brain Tumors
Preclinical / Unstaged
—Small molecule
Glioblastoma
Recurrent Glioblastoma

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
NEO100Phase 2Residual, Progressive or Recurrent Grade II or III Meningioma
Est. primary completion 2026-12-30 · NCT05023018 · CT.gov ↗
What to watch
2027 (1)
February 2027 (1)
NEO212Phase 1/2Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult, Cervical Cancer, Colorectal Cancer …
Est. primary completion 2027-02-28 · NCT06047379 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

12 August 2026Topline resultNEO100Phase 2a of intranasal NEO100 in recurrent IDH1-mutant high-grade glioma met its primary endpoint
Neonc Technologies, Inc. · Source ↗

Financial reports

Quarterly & interim (9)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$0$1.3M$6.2M$4.4M-$5.1M operating cash flowreport ↗
View 8 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$0$2.6M$2.0M$14M-$4.8M operating cash flowreport ↗
2026-Q1—$1.3M$0.1M$8.8M-$7.0M operating cash flowreport ↗
2025-Q3—$0.7M$1.5M$8.6M-$5.8M operating cash flowreport ↗
2025-Q2—$0.7M$0.1M$5.7M-$5.3M operating cash flowreport ↗
2025-Q1<$0.1M$1.0M$5.4M$38M-$5.7M operating cash flowreport ↗
2024-Q3—$1.0M$1.3M$2.2M-$3.1M operating cash flowreport ↗
2024-Q2<$0.1M$0.4M$1.5M$4.5M-$0.3M operating cash flowreport ↗
2024-Q1<$0.1M$0.6M<$0.1M$2.9M$0.1M operating cash flowreport ↗

Annual history (3 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY<$0.1M$3.6M$0.1M$16M-$20M operating cash flowreport ↗

Neonc Technologies reported revenue of $0.04M for fiscal year 2025, down 50.0% YoY, with R&D spend of $3.64M, up 19.3% YoY. The company ended the year with cash and equivalents of $0.06M and recorded a net loss of $62.15M, equating to a quarterly net burn of $62.15M.

The clinical-stage company is advancing intranasal NEO100 in a Phase IIa trial for recurrent IDH-mutant grade III/IV gliomas (20 patients enrolled) and a Phase II study in high-grade meningioma (6 patients enrolled), while the NEO212-01 Phase 1/2 dose-escalation portion was completed with the maximum tolerated dose reached at Cohort 5 (810 mg) and a recommended Phase 2 dose of 610 mg. In 2025, Neonc also acquired an artificial intelligence-driven drug discovery and 3D bioprinting intellectual property portfolio for approximately $3.5 million.

View 2 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$0.1M$3.0M$0.1M$3.0M-$4.2M operating cash flowreport ↗
2023-FY——<$0.1M—report ↗

Insider transactions

Open-market activity, trailing 12 months: 38 purchases ($2.2M), 1 sale ($17K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-13Heshmatpour Amir F · director, CEO, President, 10% ownerOpen-market purchase30,000$5.02$151KForm 4
2026-11-11Heshmatpour Amir F · director, CEO, President, 10% ownerOpen-market purchase10,000$4.49$45KForm 4
2026-11-11Heshmatpour Amir F · director, CEO, President, 10% ownerOpen-market purchase10,000$4.00$40KForm 4
2026-11-10Heshmatpour Amir F · director, CEO, President, 10% ownerOpen-market purchase50,000$4.19$210KForm 4
2026-11-10CHEN THOMAS C · director, CMO, 10% ownerOpen-market purchase2,284$4.38$10KForm 4
2026-11-09CHEN THOMAS C · director, CMO, 10% ownerOpen-market purchase2,732$3.66$10KForm 4
2026-11-09Heshmatpour Amir F · director, CEO, President, 10% ownerOpen-market purchase10,000$3.86$39KForm 4
2026-11-06Heshmatpour Amir F · director, CEO, President, 10% ownerOpen-market purchase40,000$3.39$136KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 26 reporting institutions held 2.9M shares ($20.2M, 11.2% of shares outstanding).

#InstitutionSharesValue
1Cinctive Capital Management LP1,425,526$10.0M
2BANK OF AMERICA CORP /DE/235,396$1.7M
3VANGUARD CAPITAL MANAGEMENT LLC215,700$1.5M
4BlackRock, Inc.155,838$1.1M
5Hudson Bay Capital Management LP147,360$962K
6GEODE CAPITAL MANAGEMENT, LLC126,853$890K
7MILLENNIUM MANAGEMENT LLC119,249$836K
8SUSQUEHANNA INTERNATIONAL GROUP, LLP91,036$638K
9VANGUARD FIDUCIARY TRUST CO56,016$393K
10MORGAN STANLEY51,922$364K
11683 Capital Management, LLC50,000$351K
12Westmount Partners, LLC43,320$304K
13STATE STREET CORP43,170$303K
14GOLDMAN SACHS GROUP INC35,580$249K
15NORTHERN TRUST CORP23,271$163K